drugset
drugset / Trial / NCT06168032

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

NCT06168032 ↗

Recruiting 1224 enrolled Peking Union Medical College Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.

Timeline

Start
2023-12-08
Primary completion
2026-12-08
Completion
2026-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) Vaccine — —

Indications

COVID-19 lung cancer